Celldex Therapeutics (CLDX) Total Liabilities (2016 - 2025)
Historic Total Liabilities for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to $50.1 million.
- Celldex Therapeutics' Total Liabilities rose 3434.57% to $50.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.1 million, marking a year-over-year increase of 3434.57%. This contributed to the annual value of $45.3 million for FY2024, which is 2435.54% up from last year.
- Per Celldex Therapeutics' latest filing, its Total Liabilities stood at $50.1 million for Q3 2025, which was up 3434.57% from $37.0 million recorded in Q2 2025.
- In the past 5 years, Celldex Therapeutics' Total Liabilities ranged from a high of $50.1 million in Q3 2025 and a low of $21.8 million during Q2 2023
- In the last 5 years, Celldex Therapeutics' Total Liabilities had a median value of $30.2 million in 2024 and averaged $31.2 million.
- In the last 5 years, Celldex Therapeutics' Total Liabilities skyrocketed by 7004.8% in 2022 and then plummeted by 4250.03% in 2023.
- Quarter analysis of 5 years shows Celldex Therapeutics' Total Liabilities stood at $25.2 million in 2021, then increased by 5.37% to $26.5 million in 2022, then soared by 37.41% to $36.5 million in 2023, then increased by 24.36% to $45.3 million in 2024, then rose by 10.46% to $50.1 million in 2025.
- Its Total Liabilities stands at $50.1 million for Q3 2025, versus $37.0 million for Q2 2025 and $36.5 million for Q1 2025.